Evercore ISI initiated coverage on West Pharm with a new price target
$WST
Medical/Dental Instruments
Health Care
Evercore ISI initiated coverage of West Pharm with a rating of Outperform and set a new price target of $275.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/13/2026 | $447.00 | Outperform | BNP Paribas Exane |
| 6/9/2026 | $400.00 | Equal Weight → Overweight | Barclays |
| 6/2/2026 | $375.00 | Outperform | Wolfe Research |
| 12/2/2025 | $285.00 | Equal-Weight | Morgan Stanley |
| 9/15/2025 | $311.00 | Buy | Rothschild & Co Redburn |
| 6/24/2025 | $245.00 | Equal Weight | Barclays |
| 3/18/2025 | $275.00 | Outperform | Evercore ISI |
| 2/14/2025 | $250.00 | Hold → Buy | Deutsche Bank |
4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
BNP Paribas Exane initiated coverage of West Pharm with a rating of Outperform and set a new price target of $447.00
Barclays upgraded West Pharm from Equal Weight to Overweight and set a new price target of $400.00
Wolfe Research resumed coverage of West Pharm with a rating of Outperform and set a new price target of $375.00
EXTON, Pa., July 21, 2026 /PRNewswire/ -- On July 21, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, declared its regular quarterly dividend of $0.22 per share on the Company's common stock. The dividend is payable on August 5, 2026 to shareholders of record on July 29, 2026. About WestWest Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and
EXTON, Pa., July 7, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter 2026 financial results before the market opens on Thursday, July 23, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registered telephone participants will receive the dial-in number along with a
EXTON, Pa., July 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced the company completed the sale and transfer of the manufacturing and supply rights for SmartDose® 3.5mL On-Body Delivery System and associated facilities. The transaction closed as planned on July 1, 2026. West will continue to develop and manufacture all other versions of SmartDose, including SmartDose® 10mL On-Body Delivery System, adaptive technology for larger volumes.About WestWest Pharmaceutical
8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
8-K/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
Experienced healthcare and life sciences executive to lead the Company's next phase of growth and innovationEXTON, Pa., June 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that its Board of Directors has appointed Michel Lagarde to be President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors starting August 31, 2026. He succeeds Eric M. Green, who will retire from his roles as President, CEO and Board Chair on that date. The Company also announced as part of the CEO transition that the Board has elected Lead Independent Director Robert F. Frie
EXTON, Pa., March 9, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) announced today that Eric M. Green has informed the Board of Directors that he plans to retire from his positions as President, Chief Executive Officer and Chair of the Board of the Company once his successor has been hired in order to ensure a smooth transition. The Board is engaging a leading executive recruiting firm to assist with the search for a successor and expects this transition to occur in the second half of 2026. In parallel with today's announcement, the Company is reaffirming the guidance set forth in its February 12, 2026 press release.
EXTON, Pa., July 21, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced the appointment of Robert McMahon as the company's new Chief Financial Officer (CFO), effective August 4, 2025. Mr. McMahon will succeed Bernard Birkett, CFO, who announced his intention to retire earlier this year. Mr. Birkett will assume the role of Senior Advisor to the CEO through the end of the year to ensure a seamless transition. "Bob is an accomplished CFO and business executive within the
EXTON, Pa., July 21, 2026 /PRNewswire/ -- On July 21, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, declared its regular quarterly dividend of $0.22 per share on the Company's common stock. The dividend is payable on August 5, 2026 to shareholders of record on July 29, 2026. About WestWest Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and
EXTON, Pa., July 7, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter 2026 financial results before the market opens on Thursday, July 23, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registered telephone participants will receive the dial-in number along with a
Strong Start to the Year and Raising Full-Year Revenue and EPS guidanceEXTON, Pa., April 23, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the first quarter of 2026. First-Quarter Summary (comparisons to prior-year period)Net sales of $844.9 million increased 21.0%; organic growth was 15.3%.Diluted earnings per share ("EPS") of $1.92 increased 56.1%.Adjusted-diluted EPS of $2.13 increased 46.9%.Operating cash flow was $89.9 million. C
SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)
SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)
SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)